The completion of dosing in Cohort 1 of the Phase 1/2 clinical trial is a significant milestone for Ocugen, indicating progress in its development pipeline. This news is likely to be viewed positively by investors, as it demonstrates advancement towards the potential commercialization of OCU410. The focus on Geographic Atrophy, a condition with limited treatment options, could position Ocugen in a niche market, enhancing its value proposition. However, the impact on the stock price will depend on the subsequent results regarding safety and efficacy.